Biomarkers /
NRAS
Overview
NRAS (neuroblastoma RAS viral (v-ras) oncogene homolog) encodes for the GTPase NRas protein, one of three human RAS proteins. RAS proteins are small GTPases that are central mediators downstream of growth factor receptor signaling and therefore critical for cell proliferation, survival, and differentiation. NRAS is implicated in the pathogenesis of several cancers (for review see PMID: 17384584).
NRAS is altered in 3.03% of all cancers with cutaneous melanoma, melanoma, colon adenocarcinoma, acute myeloid leukemia, and lung adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in NRAS are NRAS Mutation (2.87%), NRAS Exon 3 Mutation (1.90%), NRAS Exon 3 Missense (1.88%), NRAS Codon 61 Missense (1.72%), and NRAS Exon 2 Mutation (0.95%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of NRAS in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.